Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Itraconazole + Telisotuzumab adizutecan |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Itraconazole | Hyphanox | ITC | mTOR Inhibitor 51 | Itraconazole is an antifungal, which indirectly targets mTOR (PMID: 20176935). |
| Telisotuzumab adizutecan | ABBV 400|ABBV400|ABBV-400 | MET Antibody 37 | Telisotuzumab adizutecan (ABBV-400) is an antibody-drug conjugate (ADC) comprising an anti-MET monoclonal antibody conjugated to a topoisomerase inhibitor, which potentially inhibits tumor growth (Cancer Res (2023) 83 (7_Supplement): 6311). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06084481 | Phase I | Itraconazole + Telisotuzumab adizutecan Telisotuzumab adizutecan | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | Recruiting | USA | ISR | ESP | AUS | 4 |